APP and Alzheimer disease: Reduction of intracellular APP, Aβ- and Fe2+-related neurodegeneration (in vitro)Improved synaptic plasticity and cognitive function, and reduced AD pathology (in vitro)Established brain penetrationNo epidemiological or clinical evidence.